Moebius Medical
Tel Aviv, Israel
Dr. Wechsler has more than 25 years experience in the Israeli Biomed industry. Dr. Wechsler currently serves as the VP Research at Moebius Medical, a clinical stage company which develops MM-II, a liposomal formulation for osteoarthritis. Before that, he worked as VP R&D at Regentis Biomaterials where he was involved in the development of GelrinC, a hydrogel for cartilage repair. He also led the development of a novel biomaterial for OA. Before Regentis, he headed R&D at Prochon Biotech and Procore Biomed, which developed products for cartilage repair and regenerative medicine. Dr. Wechsler holds a PhD and MSc in life Sciences from the Weizmann Institute of Science and a BSc from McGill University.
Tuesday, October 28, 2025
10:30 AM - 12:30 PM Central Time
Disclosure(s): Moebius Medical: Employee (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing)
Tuesday, October 28, 2025
10:30 AM - 12:30 PM Central Time
Disclosure(s): Moebius Medical: Employee (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing)
